Echinocandin - Open Access .click

Results 111 to 120 of about 16,526 (218)

Estado actual de las resistencias de Candida a los fármacos antifúngidos y estudio de los mecanismos implicados [PDF]

, 2018
[ES] El género Candida se encuentra taxonómicamente ubicado dentro del reino Fungi,subreino Dikarya y orden Sacharomycetales (Bonifaz, 2012). Se trata de una levadura redonda u ovalada de 4-6 μm de tamaño denominada blastoconidio, que forma gemaciones ...
Bilbao Bilbao, Nagore
core

Echinocandin persistence directly impacts the evolution of resistance and survival of the pathogenic fungus Candida glabrata

mBio
Recent epidemiological studies documented an alarming increase in the prevalence of echinocandin-resistant (ECR) Candida glabrata blood isolates. ECR isolates are known to arise from a minor subpopulation of a clonal population, termed echinocandin ...
Amir Arastehfar +8 more
doaj +1 more source

Why do echinocandins fail? Identifying key predictors to improve clinical outcomes of candida bloodstream infections: a retrospective multicenter cohort study

International Journal of Infectious Diseases
Background: Echinocandins represent first-line therapy for Candida Bloodstream Infections (C-BSIs). Incidence of treatment failure (TF) remains high with unclear risk factors. Aim: to evaluate predictors of echinocandin TF for C-BSIs.
Davide Fiore Bavaro +27 more
doaj +1 more source

Tipping the balance both ways: drug resistance and virulence in Candida glabrata [PDF]

, 2017
Among existing fungal pathogens, Candida glabrata is outstanding in its capacity to rapidly develop resistance to currently used antifungal agents. Resistance to the class of azoles, which are still widely used agents, varies in proportion (from 5 to 20%)
Bolotin-Fukuhara, Monique +2 more
core

Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance

mSphere
Candida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj +1 more source

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. [PDF]

, 2017
Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival.
Aljurf, M +26 more
core

Empiric antibiotics for sepsis [PDF]